Tracking Thinking and Memory After CAR-T Therapy in Multiple Myeloma
Follows changes in thinking and memory in adults with multiple myeloma after CAR-T therapy.
Key facts
- Who runs it
- Wake Forest University Health Sciences
- Where
- Charlotte, United StatesSee the site
- Trial code
- Registry title
- Neurocognitive Trajectories After BCMA CAR-T
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- Nov 2026
- Expected to end
- Nov 2029
- Type of study
- Observational
- Treatments tested
- Standardized neurocognitive testing
- Record updated
- 23 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with relapsed or refractory multiple myeloma who are scheduled to receive BCMA CAR-T therapy. It studies how thinking and memory change over time.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Relapsed or refractory multiple myeloma (RRMM), scheduled for BCMA CAR-T therapy. ECOG 0-2.
- Earlier treatment
- Must be scheduled to receive BCMA CAR-T therapy. Anyone taking a benzodiazepine must be able to hold it for 3 hours before study assessments.
Main reasons for not taking part
- Active central nervous system (CNS) disease
- Known neurodegenerative disease or major neurocognitive disorder
- Stroke or traumatic brain injury (TBI) within 12 months
- Concurrent investigational neuroactive drugs
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Ability to understand and willingness to sign an IRB-approved informed consent
- Ability to retain independent decision-making capacity as per the enrolling investigator
- Age ≥ 18 years of age at the time of consent
- Scheduled to receive BCMA CAR-T therapy for RRMM as confirmed by the treating clinician
- Ability to read and understand the English language
- ECOG 0-2
- If actively taking benzodiazepine, must be able to hold for 3 hours prior to study assessments as per treating clinician
- Reliable access to internet access; a tablet, laptop and/or desktop computer with a camera; or willingness to come into the clinic to conduct study procedures as outlined in the Study Calendar- as per participant self-report
- Ability to complete required assessments, as determined by the treating clinician
Who cannot take part
- Concurrent investigational neuroactive drugs
- Active central nervous system (CNS) disease
- Known neurodegenerative disease or major neurocognitive disorder
- Stroke and/or traumatic brain injury (TBI) within 12 months
Where in United States
- Atrium Health Levine CancerCharlotte, United StatesContact: Courtney SchepelTaking people
About the trial
What the trial wants to find out
The purpose of this research study is to evaluate cognitive changes over time in participants with relapsed or refractory multiple myeloma who have received chimeric antigen receptor T-cell therapy (CAR-T).
The group in the trial
- Patients with RRMM
RRMM patients being treated with SOC commercial BCMA CAR-T therapy
Treatment: Standardized neurocognitive testing
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Longitudinal Neurocognitive Trajectories After BCMA CAR-T in Multiple Myeloma
- Plain-language title
- Tracking Thinking and Memory After CAR-T Therapy in Multiple MyelomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 23 October 2026